PHIBRO ANIMAL HEALTH CORP PAHC
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
5/9
Piotroski F — financial health
3.97
Altman Z″ — distress risk · safe
40.3%
Dividend payout · moderate
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $1.3B | $48.3M | $399.9M | — | $285.7M |
| 2024 | $1.0B | $2.4M | $313.1M | — | $256.6M |
| 2023 | $977.9M | $32.6M | $298.2M | — | $282.5M |
| 2022 | $942.3M | $49.2M | $285.4M | — | $262.4M |
| 2021 | $833.4M | $54.4M | $271.4M | — | $238.5M |
| 2020 | $800.4M | $33.6M | $256.9M | — | $188.2M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| CORCORAN E THOMAS | director | 2026-05-29 | Buy | 10,000 | $31.77 |
| BENDHEIM JACK | President and CEO | 2026-05-07 | Sell | 1,350 | $47.59 |
| BENDHEIM JACK | President and CEO | 2026-05-07 | Sell | 2,029 | $49.19 |
| BENDHEIM JACK | President and CEO | 2026-05-07 | Sell | 1,149 | $48.31 |
| BENDHEIM JACK | President and CEO | 2026-05-06 | Sell | 1,406 | $58.13 |
| BENDHEIM JACK | President and CEO | 2026-05-06 | Sell | 5,634 | $57.18 |
| BENDHEIM JACK | President and CEO | 2026-05-05 | Sell | 776 | $56.37 |
| BENDHEIM JACK | President and CEO | 2026-05-05 | Sell | 6,264 | $55.73 |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 3.97 (safe)
- Working capital / assets 0.38
- Retained earnings / assets 0.2
- EBIT / assets 0.081
- Equity / liabilities 0.266
Source: SEC EDGAR filings · CIK 0001069899 · as of 2025-06-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.